The U.S. Food and Drug Administration (FDA) has designated toripalimab (JS001) a breakthrough therapy as a potential treatment of nasopharyngeal carcinoma (NPC), one of the most common cancers in China and one lacking treatment options elsewhere. This designation is given to medications for serious or life-threatening conditions that have the potential to provide significant advantages over current alternatives, and helps to speed their development, review, and possible approval. Toripalimab, being developed by Junshi Biosciences, is the first anti-PD-1 antibody coming…
You must be logged in to read/download the full post.
The post FDA Acts to Speed Toripalimab as Potential Nasopharyngeal Cancer Treatment appeared first on BioNewsFeeds.